425 reports of this reaction
1.5% of all DOLUTEGRAVIR SODIUM reports
#15 most reported adverse reaction
OSTEOPOROSIS is the #15 most commonly reported adverse reaction for DOLUTEGRAVIR SODIUM, manufactured by ViiV Healthcare Company. There are 425 FDA adverse event reports linking DOLUTEGRAVIR SODIUM to OSTEOPOROSIS. This represents approximately 1.5% of all 28,565 adverse event reports for this drug.
Patients taking DOLUTEGRAVIR SODIUM who experience osteoporosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OSTEOPOROSIS is a less commonly reported adverse event for DOLUTEGRAVIR SODIUM, but still significant enough to appear in the safety profile.
In addition to osteoporosis, the following adverse reactions have been reported for DOLUTEGRAVIR SODIUM:
The following drugs have also been linked to osteoporosis in FDA adverse event reports:
OSTEOPOROSIS has been reported as an adverse event in 425 FDA reports for DOLUTEGRAVIR SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
OSTEOPOROSIS accounts for approximately 1.5% of all adverse event reports for DOLUTEGRAVIR SODIUM, making it a notable side effect.
If you experience osteoporosis while taking DOLUTEGRAVIR SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.